CTLA4 and non-small cell lung carcinoma: After an early study showed the durable abscopal effect of RT and ipilimumab in a single patient [169], RT and CTLA-4 blockade were shown to induce systemic antitumor T-cell responses in metastatic chemo-refractory NSCLC in a larger clinical trial [174].